FDA Approves Medtronic MiniMed™ 780G System – World’s First Insulin Pump with Meal Detection Technology

On April 21, 2023, Medtronic plc (NYSE: MDT), a global leader in medical technology, announced FDA approval of its MiniMed 780G system with the Guardian 4 sensor, which requires no fingersticks while in SmartGuard technology.

This milestone marks the approval of the only system with meal detection technology that provides automatic adjustments and corrections to sugar levels every 5 minutes for both basal (background) and bolus (mealtime) insulin needs.

The system includes insulin to help account for times when users forget to bolus or underestimate the number of carbs in their meals.

Key System Features

The MiniMed 780G system has the lowest glucose target setting (as low as 100 mg/dL) of any automated insulin pump on the market, closely matching the average glucose of someone who does not have diabetes.

With this option enabled, the pump will “treat to target,” automatically delivering basal insulin adjustments and autocorrections to a predefined target. It is also the only pump with an infusion set that can be worn for up to 7 days, doubling wear time with advanced materials that help reduce insulin preservative loss, maintain insulin flow and stability, and reduce the risk of infusion set occlusion.

The MiniMed 780G system, when combined with the new Guardian 4 sensor, which requires no fingersticks with SmartGuard technology, delivers a user-friendly design, with 94% of users satisfied with the impact the system has on their quality of life. Users also reported staying in SmartGuard technology 95% of the time.

About Medtronic

Medtronic plc, based in Dublin, Ireland, is one of the world’s largest medical technology, services, and solutions companies, relieving pain, restoring health, and extending life for millions of people worldwide.

Medtronic employs over 90,000 people worldwide, providing services to physicians, hospitals, and patients in over 150 countries. The company is committed to working with stakeholders all over the world to advance healthcare.

For more information, please visit: Medtronic MiniMed™ 780G System

FDA News and Insights – Recommended Articles 

• FDA Grants Breakthrough Therapy Designation to Madrigal’s Resmetirom
• FDA Grants Fast Track Designation to Botensilimab Plus Balstilimab
• FDA Orphan Drug Designation for XORTX ADPKD Treatment
• Orphan Drug Designation: Key Developments in August 2023
• Orphan Drug Designation: Updates and Highlights for September 2023
• Lenire: Innovative Treatment for Tinnitus Relief
• LuxCreo Launches LuxAlign: 3D Printed Clear Aligners Revolutionizing Dental Care